ACROBAT Clinical Research Trials
The ACROBAT studies are evaluating the ability of an investigational once daily oral medication to help manage elevated IGF-1 levels and symptoms of acromegaly. There are two ACROBAT studies and one of them may be right for you. These studies are being conducted at specialized endocrinology centers around the world, including centers in Europe, the United Kingdom, and the United States.
Acrobat Evolve is for patients living with acromegaly. Patients may be eligible for this study with a confirmed diagnosis of acromegaly that is well controlled on stable doses of octreotide LAR (Sandostatin LAR®) or lanreotide depot (Somatuline Depot®).
Acrobat Edge is for patients living with acromegaly. Patients may be eligible for this study with a confirmed diagnosis of acromegaly who do not adequately respond to octreotide LAR (Sandostatin LAR®) or lanreotide depot (Somatuline Depot®) therapy alone or who may be on other somatostatin analogue therapy regimens including combination therapies.
About the Drug
The new investigational medication is called paltusotine (also known as CRN00808). An investigational drug is one that has not been approved by any health authority for the treatment of acromegaly. It was intended to reduce growth hormone production by the pituitary gland and thereby reduce the amount of IGF-1 present in the blood. ln an initial Phase I clinical trial, once daily oral administration of paltusotine (CRN00808) was shown to reduce growth hormone and IGF-1 in healthy volunteers. It was developed at Crinetics Pharmaceuticals in San Diego, California.